Kalobios Pharmaceuticals, Inc.

Medarex Inc.

Oxford Biomedica (uk) Limited

Allakos Inc.

Oxford Biomedica, Inc.

Ludwig Institute for Cancer Research Limited

Beijing University of Technology

Humanigen, Inc.

Monash University

Kalobios, Inc.

Christopher Robert Bebbington

Geoffrey T Yarranton

Susan Mary Kingsman

Kevin Alan Myers

Nenad Tomasevic

Kenneth Luehrsen

Fiona Margaret Ellard

Miles William Carroll

Lesley B Pickford

Sanjeev Gangwar

David J King

Matthew H Nieder

Alan John Kingsman

Mark Baer

Varghese Palath

Rustom Falahati

Josephine M Cardarelli

Francis J Carr

Sarah Lee Pogue

Chin Pan

Stephen Williams

Tseng-hui Timothy Chen

Pina M Cardarelli

David Martinez

Thomas Jay Lobl

Susan Marie Kingsman

Andre Trouet

Vincent Dubois

Mark Uden

Jason Williams

Kyriacos Mitrophanos

Christina Yi

Wouter Korver

Bradford Andrew Youngblood

David M Martinez

Bo Yu

Jeng-Horng Her

Andrew Ewart Scott

Peter Flynn

Robert F Balint

Martin Lackmann

Andrew Mark Scott

David John Matthews

John Leung

Abigail Lamikanra

Miles William Carrol

Kenneth R Luehrsen

Suzy El Bader

Carolina Rita Sousa Fernandes

Swathi Sujatha-Bhaskar

Carmelina Murone

Catherine To

David King

The invention provides methods and compositions for the treatment of cancer using anti-Siglec-7 antibodies that have reduced effector function.

Anti-Siglec-7 antibodies having reduced effector function

The invention provides methods and compositions for the treatment of cancer using anti-Siglec7 antibodies.

Anti-Siglec-7 antibodies for the treatment of cancer

The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.

Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis

The invention provides methods for generating human antibodies with the specificity of a reference antibody by replacement of portions of the Vand Vsequences of the reference antibody with sequences from human antibody repertoires. The invention also provides novel compositions comprising hybrid immunoglobulin variable domains containing a combination of frameworks (FRs) and CDRs from different antibody clones.

Immunoglobulin variable region cassette exchange

The invention provides methods and compositions for the prevention or treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. In particular, the invention provides methods for the prevention or treatment of fibrotic diseases and pre-fibrotic diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention or treatment fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis.

Methods and compositions for treating fibrotic diseases

The invention provides methods and compositions for the prevention and treatment of advanced systemic mastocytosis such as systemic mastocytosis with an associated hematologic non-mast-cell lineage disease (SM-AHNMD). In particular, the invention provides methods for the prevention and treatment of advanced systemic mastocytosis through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of advanced systemic mastocytosis such as SM-AHNMD.

Methods and compositions for treating systemic mastocytosis

The invention provides methods and compositions for the prevention and treatment of Siglec-8 associated diseases such as chronic rhino sinusitis with concomitant asthma and aspirin-exacerbated respiratory disease. In particular, the invention provides methods for the prevention and treatment of Siglec-8 associated diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of Siglec-8 associated diseases such as chronic rhinosinusitis with concomitant asthma and aspirin-exacerbated respiratory disease.

Methods and compositions for treating Siglec-8 associated diseases

The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.

Anti-Siglec-8 antibodies and methods of use thereof

The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.

Antibodies to EphA3

The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries.

Secretion of antibodies without signal peptides from bacteria

The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.

Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow

The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.

Anti-EMR1 antibodies

The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.

Antibodies to granulocyte-macrophage colony-stimulating factor

The current invention provides high-affinity antibodies to thePcrV protein that have reduced immunogenicity when administered to treatinfections.

[object Object]

The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.

Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3

Growing community of inventors

San Mateo, CA, United States of America

Christopher Robert Bebbington